Teleflex Incorporated (NYSE:TFX – Free Report) – Equities research analysts at Wolfe Research lowered their Q2 2026 earnings estimates for shares of Teleflex in a report released on Monday, May 11th. Wolfe Research analyst M. Polark now anticipates that the medical technology company will post earnings per share of $1.49 for the quarter, down from their prior estimate of $1.51. The consensus estimate for Teleflex’s current full-year earnings is $6.80 per share. Wolfe Research also issued estimates for Teleflex’s Q3 2026 earnings at $2.32 EPS, Q4 2026 earnings at $2.97 EPS, FY2026 earnings at $8.05 EPS, Q1 2027 earnings at $2.54 EPS, Q2 2027 earnings at $2.66 EPS, Q3 2027 earnings at $2.88 EPS, Q4 2027 earnings at $3.47 EPS, FY2027 earnings at $11.53 EPS, Q1 2028 earnings at $2.86 EPS and FY2028 earnings at $12.84 EPS.
Teleflex (NYSE:TFX – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The medical technology company reported $1.39 EPS for the quarter, beating the consensus estimate of $1.21 by $0.18. Teleflex had a negative net margin of 35.88% and a positive return on equity of 13.29%. The business had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. During the same quarter in the prior year, the firm earned $1.44 EPS. The firm’s revenue was up 32.3% compared to the same quarter last year. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS.
Check Out Our Latest Analysis on TFX
Teleflex Stock Down 0.6%
Shares of TFX opened at $129.00 on Wednesday. The stock has a market capitalization of $5.71 billion, a price-to-earnings ratio of -5.66, a PEG ratio of 0.95 and a beta of 0.82. Teleflex has a 52 week low of $100.18 and a 52 week high of $139.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55. The stock has a fifty day moving average of $120.22 and a 200-day moving average of $116.70.
Teleflex Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.1%. The ex-dividend date was Friday, March 6th. Teleflex’s dividend payout ratio (DPR) is currently -5.96%.
Institutional Trading of Teleflex
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Empowered Funds LLC grew its holdings in Teleflex by 15.8% during the first quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock worth $233,000 after buying an additional 230 shares in the last quarter. Jane Street Group LLC grew its stake in shares of Teleflex by 42.6% in the 1st quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock worth $877,000 after acquiring an additional 1,895 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Teleflex by 32.7% in the 2nd quarter. American Century Companies Inc. now owns 13,640 shares of the medical technology company’s stock worth $1,614,000 after acquiring an additional 3,360 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Teleflex by 1.2% in the second quarter. Invesco Ltd. now owns 135,516 shares of the medical technology company’s stock valued at $16,040,000 after purchasing an additional 1,659 shares during the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Teleflex by 108.1% during the second quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock valued at $119,000 after purchasing an additional 521 shares in the last quarter. 95.62% of the stock is owned by institutional investors.
Key Headlines Impacting Teleflex
Here are the key news stories impacting Teleflex this week:
- Positive Sentiment: Needham & Company reiterated a Buy rating and set a $147 price target, while also forecasting strong future earnings growth, including FY2028 EPS of $12.18 and Q1 2028 EPS of $2.90. Teleflex analyst estimate report
- Positive Sentiment: Citizens JMP published bullish multi-year estimates for Teleflex, projecting FY2027 EPS of $10.50 and quarterly EPS progression through 2027, suggesting confidence in the company’s earnings trajectory. Teleflex analyst estimate report
- Neutral Sentiment: Truist Financial reaffirmed its Hold rating but raised its price target to $143 from $135, signaling a somewhat improved valuation view without a full bullish upgrade. Teleflex hold rating reaffirmed at Truist Financial
- Neutral Sentiment: Analyst consensus for Teleflex’s current fiscal year remains around $6.75-$6.80 EPS, which provides a stable backdrop but does not by itself signal a new catalyst. Teleflex analyst estimate report
About Teleflex
Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.
The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.
Read More
- Five stocks we like better than Teleflex
- Ally Financial Is Back to Basics—And Investors Are Watching
- Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.
